Current conception about the pathogenesis and intensive care of severe COVID-19 (review)

M. Georgiyants, V. Korsunov, S. Dubrov, O. Loskutov, N. Bohuslavska, Vadim Nikonov, L. Cherkashyna, O. Oparin, P. Nartov, M. Holianishchev
{"title":"Current conception about the pathogenesis and intensive care of severe COVID-19 (review)","authors":"M. Georgiyants, V. Korsunov, S. Dubrov, O. Loskutov, N. Bohuslavska, Vadim Nikonov, L. Cherkashyna, O. Oparin, P. Nartov, M. Holianishchev","doi":"10.15587/2519-4798.2021.241456","DOIUrl":null,"url":null,"abstract":"The aim of the research. The aim of this work was to summarize the scientific literature data on the pathogenesis and intensive care of the severe course of coronavirus infection. \nMaterials and methods. Databases such as PubMed, Google Scholar, Scopus and Web Of Science 2020-2021 were used for literary searches. \nResults. An intense inflammatory response against the SARS-CoV-2 virus in COVID-19 patients causes a cytokine storm and hypercoagulability with the development of acute respiratory distress syndrome (ARDS) and multiple organ failure. Approximately 17 % to 35 % of hospitalized patients with COVID-19 are treated in the intensive care unit, most often due to hypoxemic respiratory failure and the development of ARDS, and between 29 % and 91 % of patients in intensive care units require invasive ventilation. \nIn addition to acute respiratory failure, hospitalized patients may have acute renal failure (9 %), liver dysfunction (19 %), coagulation disorders (10 %–25 %), and septic shock (6 %). \nMore than 75 % of hospitalized patients require additional oxygen therapy. Respiratory support could vary from the need for oxygen supplementation through a nasal catheter to invasive ventilation or extracorporeal membrane oxygenation in patients with the most severe ARDS. \nThe uncontrolled inflammation and coagulation seen in COVID-19 patients is similar to multifactorial ARDS, where a plethora of evidence has demonstrated the ability of long-term corticosteroid therapy (CST) to reduce inflammation-coagulation-fibroproliferation and accelerate recovery. \nWith regard to the assessment of the benefits of therapeutic anticoagulation in patients with elevated D-dimer, the question has not yet been finally resolved, and research devoted to this is still ongoing. \nConclusions. The approaches to respiratory, anticoagulant, anti-inflammatory therapy in critically ill patients with COVID-19 require further research to determine the optimal treatment tactics","PeriodicalId":21672,"journal":{"name":"ScienceRise: Medical Science","volume":"32 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ScienceRise: Medical Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15587/2519-4798.2021.241456","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The aim of the research. The aim of this work was to summarize the scientific literature data on the pathogenesis and intensive care of the severe course of coronavirus infection. Materials and methods. Databases such as PubMed, Google Scholar, Scopus and Web Of Science 2020-2021 were used for literary searches. Results. An intense inflammatory response against the SARS-CoV-2 virus in COVID-19 patients causes a cytokine storm and hypercoagulability with the development of acute respiratory distress syndrome (ARDS) and multiple organ failure. Approximately 17 % to 35 % of hospitalized patients with COVID-19 are treated in the intensive care unit, most often due to hypoxemic respiratory failure and the development of ARDS, and between 29 % and 91 % of patients in intensive care units require invasive ventilation. In addition to acute respiratory failure, hospitalized patients may have acute renal failure (9 %), liver dysfunction (19 %), coagulation disorders (10 %–25 %), and septic shock (6 %). More than 75 % of hospitalized patients require additional oxygen therapy. Respiratory support could vary from the need for oxygen supplementation through a nasal catheter to invasive ventilation or extracorporeal membrane oxygenation in patients with the most severe ARDS. The uncontrolled inflammation and coagulation seen in COVID-19 patients is similar to multifactorial ARDS, where a plethora of evidence has demonstrated the ability of long-term corticosteroid therapy (CST) to reduce inflammation-coagulation-fibroproliferation and accelerate recovery. With regard to the assessment of the benefits of therapeutic anticoagulation in patients with elevated D-dimer, the question has not yet been finally resolved, and research devoted to this is still ongoing. Conclusions. The approaches to respiratory, anticoagulant, anti-inflammatory therapy in critically ill patients with COVID-19 require further research to determine the optimal treatment tactics
重症COVID-19发病机制及重症监护现状(综述)
研究的目的。本工作的目的是总结有关冠状病毒感染重症病程的发病机制和重症监护的科学文献资料。材料和方法。文献检索使用了PubMed、Google Scholar、Scopus和Web Of Science 2020-2021等数据库。结果。COVID-19患者对SARS-CoV-2病毒的强烈炎症反应导致细胞因子风暴和高凝血症,发展为急性呼吸窘迫综合征(ARDS)和多器官衰竭。约17%至35%的COVID-19住院患者在重症监护室接受治疗,最常见的原因是低氧性呼吸衰竭和急性呼吸窘迫综合征的发展,29%至91%的重症监护室患者需要有创通气。除急性呼吸衰竭外,住院患者还可能出现急性肾功能衰竭(9%)、肝功能障碍(19%)、凝血功能障碍(10% - 25%)和感染性休克(6%)。超过75%的住院患者需要额外的氧气治疗。在最严重的ARDS患者中,呼吸支持可以从需要通过鼻导管补充氧气到需要有创通气或体外膜氧合。在COVID-19患者中观察到的不受控制的炎症和凝血与多因素ARDS相似,其中大量证据表明,长期皮质类固醇治疗(CST)能够减少炎症-凝血-纤维增殖并加速恢复。关于对d -二聚体升高的患者进行治疗性抗凝治疗的益处的评估,这个问题尚未最终解决,对此的研究仍在进行中。结论。COVID-19危重症患者的呼吸、抗凝、抗炎治疗方法有待进一步研究,以确定最佳治疗策略
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
47
审稿时长
6 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信